article thumbnail

Omega Therapeutics Entered into a Clinical Supply Agreement with Roche to Evaluate OTX-2002 for Hepatocellular Carcinoma

PharmaShots

Shots: The companies collaborated to evaluate the safety, tolerability, PK, PD & preliminary antitumor activity of OTX-2002 as monotx. The preliminary results from the monotx.

article thumbnail

STAT+: Intellia says CRISPR treatment safely corrects DNA of six patients with rare disease

STAT

Preliminary results from the study — just the second to show that CRISPR-based gene editing can be delivered systemically and performed in vivo, or inside the body — found that the treatment, NTLA-2002, reduced levels of the disease-causing protein, kallikrein, by 65% and 92% in the low- and high-dose cohort, respectively.

353
353
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Opinion: What Rosalynn Carter understood about mental health

STAT

Often she was called upon to guide, inform, or brainstorm, as she did in 2002 when Mike Hogan, chair of President George W.

355
355
article thumbnail

Scientists are finding increasing evidence for a link between air pollution and neurodegenerative diseases like Alzheimer’s

STAT

In 2002, toxicologist and neuropathologist Lilian Calderón-Garcidueñas, who grew up east of the metropolis and attended medical school in the city, decided to look at the brains of 40 dogs that had lived either in the city’s polluted valley or in the cleaner air of Tlaxcala, a state on its eastern edge.

article thumbnail

STAT+: Medicare is urged to consider Amgen patent maneuvers when negotiating the price for a drug

STAT

Here’s the backstory: Enbrel was the centerpiece of a 2002 deal in which Amgen acquired another company called Immunex that had developed the medicine. But Public Citizen maintains Medicare officials should consider the ongoing cost of the patenting tactics when negotiating a price.

article thumbnail

Watch: Blockbuster drug Humira has new competition. Here’s why that matters

STAT

Humira has been the world’s best-selling medicine since it arrived on the market in 2002. Now, it is finally getting competition with the release of Amgen’s biosimilar drug, Amjevita.

article thumbnail

How telehealth startups are trying to fill the menopause care vacuum

STAT

But in 2002, the therapy went into a free-fall when a landmark trial suggested treating menopause with estrogen and progesterone increased the risk of breast cancer and cardiovascular disease.

244
244